Immunological adjuvant with immunity vegulating agent for treating and preventing diabetic from insulin-dependent

An immunomodulator, human insulin technology, applied in DNA recombination technology, protein separation and purification technology and medical related fields, can solve the problems that polypeptide vaccines cannot enhance immunogenicity and cannot be used in human body
CN1831012AInactive Publication Date: 2006-09-13CHINA PHARM UNIV
0 Cites 11 Cited by

Patent Information

Authority / Receiving Office
CN · China
Current Assignee / Owner
CHINA PHARM UNIV
Publication Date
2006-09-13
Estimated Expiration
Not applicable · inactive patent

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The invention provides the immunomodulator with the free adjuvant having the function of preventing and curing the insulin-dependent diabetes mellitus. Aiming at the weak immunogenicity, the antigen epitope polypeptide gene (a length of antigen epitope p277 rooted from human HSP60) is associated repeatedly six times and inserted repeatedly into the backward position of the heat shock protein HSP65 gene rooted from the mycobacterium bovis, the fusing expression between the repeat series connecting antigen polyeptide and the HSP65 is realized. The produced fusing albumen did not need the adjuvant; the antigen polyeptide don't need be coupled with the carrier chemistry to the immunity. The fusing albumen can inspire the organism to produce the high titer aiming at p277 by means of the mucous membrane immunity, so the nosogeny of NOD chmice diabetic are depressed highly. The invention can prevent the 1 type and 1.5 type diabete characterized in depending on the insulin.
Need to check novelty before this filing date? Find Prior Art

Description

technical field

[0001] The invention relates to DNA recombination technology, protein separation and purification technology and medical related fields. More specifically, the present invention relates to the construction, expression and separation and purification of fusion protein HSP65-6×p277. In the field of medicine, the invention is an immunomodulator, which can be used for preventing and treating human insulin-dependent diabetes. Background technique

[0002] Human insulin-dependent diabetes mellitus (insulin-dependent diabetes mellitus, IDDM), including type 1 diabetes and type 1.5 diabetes. Type 1 diabetes is an autoimmune disease with familial inheritance, and the majority of patients are teenagers. The main manifestations are the destruction of most of the islet β cells and the absolute lack of insulin. At present, there is no effective treatment, and patients need to rely on insulin for life, which is very painful. After 1992, according to the WHO Diamond Pro...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More